References
- Ghoreschi K, Balato A, Enerbäck C, et al. Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis. Lancet. 2021;397(10275):1–8. doi: 10.1016/S0140-6736(21)00184-7.
- Jeon C, Sekhon S, Yan D, et al. Monoclonal antibodies inhibiting IL-12, -23, and -17 for the treatment of psoriasis. Hum Vaccin Immunother. 2017;13(10):2247–2259. doi: 10.1080/21645515.2017.1356498.
- Eshwar V, Kamath A, Shastry R, et al. A review of the safety of interleukin-17A inhibitor secukinumab. Pharmaceuticals (Basel). 2022;15(11):1365. doi: 10.3390/ph15111365.
- Lebwohl M, Strober B, Menter A, et al. Phase 3 studies comparing brodalumab with ustekinumab in psoriasis. N Engl J Med. 2015;373(14):1318–1328. doi: 10.1056/NEJMoa1503824.
- Mease P, Roussou E, Burmester GR, et al. Safety of ixekizumab in patients with psoriatic arthritis: results from a pooled analysis of three clinical trials. Arthritis Care Res (Hoboken). 2019;71(3):367–378. doi: 10.1002/acr.23738.
- Papp KA, Leonardi C, Menter A, et al. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N Engl J Med. 2012;366(13):1181–1189. doi: 10.1056/NEJMoa1109017.
- van de Kerkhof PC, Griffiths CE, Reich K, et al. Secukinumab long-term safety experience: a pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis. J Am Acad Dermatol. 2016;75(1):83–98.e4. doi: 10.1016/j.jaad.2016.03.024.
- Witowski J, Pawlaczyk K, Breborowicz A, et al. IL-17 stimulates intraperitoneal neutrophil infiltration through the release of GRO alpha chemokine from mesothelial cells. J Immunol. 2000;165(10):5814–5821. doi: 10.4049/jimmunol.165.10.5814.
- Medzhitov R. Recognition of microorganisms and activation of the immune response. Nature. 2007;449(7164):819–826. doi: 10.1038/nature06246.
- Stark MA, Huo Y, Burcin TL, et al. Phagocytosis of apoptotic neutrophils regulates granulopoiesis via IL-23 and IL-17. Immunity. 2005;22(3):285–294. doi: 10.1016/j.immuni.2005.01.011.
- Weaver CT, Hatton RD, Mangan PR, et al. IL-17 family cytokines and the expanding diversity of effector T cell lineages. Annu Rev Immunol. 2007;25(1):821–852. doi: 10.1146/annurev.immunol.25.022106.141557.
- Smith E, Zarbock A, Stark MA, et al. IL-23 is required for neutrophil homeostasis in normal and neutrophilic mice. J Immunol. 2007;179(12):8274–8279. doi: 10.4049/jimmunol.179.12.8274.
- Blauvelt A, Papp KA, Griffiths CE, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. J Am Acad Dermatol. 2017;76(3):405–417. doi: 10.1016/j.jaad.2016.11.041.
- Deodhar A, Gottlieb AB, Boehncke WH, et al. Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study. Lancet. 2018;391(10136):2213–2224. doi: 10.1016/S0140-6736(18)30952-8.
- Leonardi CL, Kimball AB, Papp KA, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet. 2008;371(9625):1665–1674. doi: 10.1016/S0140-6736(08)60725-4.
- Yamaguchi M, Inomata S, Harada S, et al. Establishment of the MID-NET® medical information database network as a reliable and valuable database for drug safety assessments in Japan. Pharmacoepidemiol Drug Saf. 2019;28(10):1395–1404. doi: 10.1002/pds.4879.
- Yamada K, Itoh M, Fujimura Y, et al. The utilization and challenges of Japan’s MID-NET® medical information database network in post-marketing drug safety assessments: a summary of pilot pharmacoepidemiological studies. Pharmacoepidemiol Drug Saf. 2019;28(5):601–608. doi: 10.1002/pds.4777.
- Pharmaceuticals and Medical Devices Agency. Information for studies approved through a discussion by the expert committee of MID-NET®; 2024. [in Japanese]. https://www.pmda.go.jp/safety/mid-net/0010.html.
- Andrès E, Villalba NL, Zulfiqar AA, et al. State of art of idiosyncratic drug-induced neutropenia or agranulocytosis, with a focus on biotherapies. J Clin Med. 2019;8(9):1351. doi: 10.3390/jcm8091351.
- Andrès EVN, Zulfiqar A-A, Maouche Y, et al. TNF-alpha inhibitors and neutropenia: current state of art. J Cell Immunol. 2020;2(4):157–164.
- Dogra S, Khullar G. Tumor necrosis factor-α antagonists: side effects and their management. Indian J Dermatol Venereol Leprol. 2013;79 Suppl 7(7):S35–S46. doi: 10.4103/0378-6323.115526.
- Bessissow T, Renard M, Hoffman I, et al. Review article: non-malignant haematological complications of anti-tumour necrosis factor alpha therapy. Aliment Pharmacol Ther. 2012;36(4):312–323. doi: 10.1111/j.1365-2036.2012.05189.x.
- The package insert of Humira® Syringe and Humira® Pen. 2024. [in Japanese]. https://www.pmda.go.jp/PmdaSearch/iyakuDetail/ResultDataSetPDF/112130_3999426G3027_1_10.
- Carrascosa JM, Del-Alcazar E. Apremilast for psoriasis treatment. G Ital Dermatol Venereol. 2020;155(4):421–433. doi: 10.23736/S0392-0488.20.06684-5.
- The package insert of Otezla® Tablets. 2024. [in Japanese]. https://www.pmda.go.jp/PmdaSearch/iyakuDetail/ResultDataSetPDF/112292_3999042F1025_3_03
- Pharmaceuticals and Medical Devices Agency. The review report of Otezla® tablets. 2024. [in Japanese]. https://www.pmda.go.jp/drugs/2016/P20161220001/380809000_22800AMX00729000_A100_1.pdf.
- National Cancer Institute. Common terminology criteria for adverse events (CTCAE) Version 5.0. 2024. https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf.
- Japan Clinical Oncology Group. JCOG common reference intervals. 2024. [in Japanese]. https://jcog.jp/assets/JCOG_kyouyoukijunchi_50_20201221.pdf.
- Gordon KB, Blauvelt A, Papp KA, et al. Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis. N Engl J Med. 2016;375(4):345–356. doi: 10.1056/NEJMoa1512711.
- Pharmaceuticals and Medical Devices Agency. Act on the pharmaceuticals and medical devices agency (act no.192 of 2002). [in Japanese]. https://elaws.e-gov.go.jp/document?lawid=414AC0000000192.
- Pharmaceuticals and Medical Devices Agency. Pharmacoepidemiological studies for drug safety assessment under MIHARI framework. 2024. [in Japanese]. https://www.pmda.go.jp/safety/surveillance-analysis/0045.html.